About Cyprotex plc
Cyprotex PLC is a holding company. The Company and its subsidiaries are engaged in the provision of in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) and Pharmacokinetic (PK) information to the pharmaceutical and biotechnology industries. It offers a range of different services in the areas of ADME-PK, in vitro toxicology, biosciences, in silico prediction, in vitro skin and ocular testing, endocrine disruption and physicochemical profiling. Its in vitro ADME and drug metabolism and pharmacokinetics (DMPK) services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis. It operates mainly in North America, Mainland Europe and the United Kingdom. It serves pharmaceutical, biotech, cosmetics, personal care, household products, chemical, agrochemical and tobacco markets. Its subsidiaries include Cyprotex Discovery Limited and Cyprotex US, LLC.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: CRX
- Previous Close: $2.00
- 50 Day Moving Average: $158.05
- 200 Day Moving Average: $139.40
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Market Cap: $N/A
Consensus Ratings for Cyprotex plc (LON:CRX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Cyprotex plc (LON:CRX)
(Data available from 2/25/2015 forward)
|11/17/2015||N+1 Singer||Reiterated Rating||corporate|
Earnings History for Cyprotex plc (LON:CRX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Cyprotex plc (LON:CRX)
Current Year EPS Consensus Estimate: $6.40 EPS
Dividend History for Cyprotex plc (LON:CRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cyprotex plc (LON:CRX)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Cyprotex plc (LON:CRX)
What is Cyprotex plc's stock symbol?
Cyprotex plc trades on the London Stock Exchange (LON) under the ticker symbol "CRX."
When will Cyprotex plc announce their earnings?
Cyprotex plc is scheduled to release their next quarterly earnings announcement on Tuesday, August, 2nd 2016.
How do I buy Cyprotex plc stock?
Shares of Cyprotex plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of Cyprotex plc stock cost?
One share of Cyprotex plc stock can currently be purchased for approximately GBX 160.50.